继打出"创新药直营""剥离非优质资产聚焦主业""发布定增预案"等一整套促进创新药发展的组合拳之 后，罗欣药业本次收购少数股东股权，全资控股北京健康这一动作，背后蕴藏了哪些玄机？ 据悉，北京健康是罗欣药业旗下控股子公司，其核心业务是罗欣药业"替戈拉生片"(泰欣赞)的销售。据 悉，目前该产品已进院超过2500家，市场覆盖全国超过30个省份，米内网数据显示，在中国公立医疗机 构终端，泰欣赞实现快速成长，销售额已超6.3亿元，伴随该产品新适应症"与适当的抗生素联用以根除 幽门螺杆菌"纳入医保，2026年泰欣赞销量或将迎来爆发式增长，大幅拉动公司业绩上涨。 资产评估报告显示，北京健康2025年1月份至10月份净利润为8184.76万元，目前已实现盈利，基于其核 心产品泰欣赞良好的销售趋势，未来预期获利能够可靠估计，北京健康具备持续稳定的盈利能力，或将 呈井喷式增长。 与此同时，罗欣药业积极探索、拓展创新药多元化销售路径，已在全国布局院边关联药店合作，并率先 在浙江省开展连锁药店销售试点，2026年有望逐步推广至全国零售终端市场。尤为值得一提的是，其电 商业务线于2月9日传来好消息，泰欣赞作为中国首款自主研发的钾离子竞争 ...

公司已于2026年1月完成乐康制药100%股权转让(价格6250万元)，并于2025年12月完成罗欣安若维他 20%股权转让。这些处置有助于减少非经营性损益拖累，后续亏损影响将逐步消除。 经济观察网罗欣药业（002793）近期发布2025年业绩预告，预计归母净利润亏损显著收窄，同时核心创 新药替戈拉生片商业化放量，研发管线取得关键进展。 业绩经营情况 公司于2026年1月30日发布业绩预告，预计2025年归母净利润亏损收窄至-2.5亿元至-3.4亿元，较2024年 同期亏损(-9.65亿元)显著改善。扣非净利润预计为-2.6亿元至-3.5亿元。后续需关注审计机构的最终审计 结果，正式年报预计在2026年4月前披露。 业务进展情况 国家1类创新药替戈拉生片(泰欣赞)的三大适应症已全面纳入2025年版国家医保目录，支付端障碍消 除。2025年上半年，该产品进院数量激增近2500家，销售量同比增长约140%。未来其销售规模效应和 运营效率的提升值得跟踪。 产品研发进展 公司重点研发的注射用LX22001目前已进入Ⅱ期临床试验阶段；普卡那肽片Ⅲ期临床研究报告已完成定 稿，正推进地产化落地。这些创新药进展可能影响公司长 ...

Core Viewpoint - Recent asset transactions by Luoxin Pharmaceutical highlight the company's ongoing financial struggles, with significant losses and high debt levels prompting asset sales at steep discounts [1][2][6] Financial Performance - As of September 30, 2025, Luoxin Pharmaceutical's total assets were 12.00 billion, with total liabilities at 4.68 billion, resulting in a debt ratio of 61.65% [2][8] - The company reported a net loss of 1.44 billion for the first three quarters of 2025, following a loss of 14.48 billion in 2022 and 6.39 billion in 2023, totaling over 28 billion in losses over three years [10][11] - The company's cash reserves have drastically decreased from 20.02 billion at the end of 2021 to 3.93 billion by mid-2025, a decline of over 80% [11] Asset Sales - Luoxin Pharmaceutical sold its subsidiary, Lekang Pharmaceutical, for 62.5 million, significantly below its net asset value of 73.24 million and only 15% of its registered capital of 420 million [1][6] - The initial listing price for Lekang was 190 million, but after multiple price reductions, it was sold at a 67% discount [8] Business Challenges - The company's core generic drug business has been severely impacted by policy changes, with revenue from generics accounting for approximately 98% of total income, while the average gross margin in the industry has dropped from 75% in 2020 to about 60% [11] - Luoxin's revenue has plummeted from a peak of 6.48 billion in 2021 to 2.65 billion in 2024, indicating a significant contraction in business scale [10] Innovation and R&D - Despite the financial difficulties, Luoxin's innovative drug, Tegoprazan, has shown promising sales, exceeding 2.7 billion in the first half of 2025, marking a nearly 140% increase [12] - However, the company has reduced its R&D spending from 2.05 billion in 2022 to 0.63 billion in the first three quarters of 2025, indicating a shift towards marketing over research [12][13] - Luoxin plans to raise up to 842.4 million through a private placement to support R&D and working capital, but this funding will take time to materialize [12]

Core Viewpoint - 罗欣药业 is strategically focusing on the pharmaceutical industry, with significant growth in its core innovative drug, 泰欣赞, and plans for further development in the digestive system field. Group 1: Company Performance - As of December 31, 2025, 罗欣药业's stock closed at 4.8 yuan, down 1.44% from the previous week, with a total market capitalization of 5.22 billion yuan, ranking 97th in the chemical pharmaceutical sector [1] - 泰欣赞's sales volume increased by nearly 140% year-on-year, with the number of hospitals using the drug approaching 2,500 [1][4] - The gross profit margin for the first three quarters reached 51.8%, and operating cash flow turned positive at 280 million yuan [4] Group 2: Product Development - 泰欣赞 has achieved full coverage in the medical insurance directory for its three indications: gastroesophageal reflux disease, duodenal ulcers, and eradication of Helicobacter pylori [1][4] - The drug's advantages over PPI include rapid onset, prolonged acid suppression, and effective control of nighttime acid breakthrough [1] - The company is advancing its research pipeline, with the injection drug LX22001 entering phase II clinical trials and the report for the phase III clinical study of 普卡那肽片 completed [1] Group 3: Strategic Initiatives - 罗欣药业 plans to raise up to 842.4 million yuan through a refinancing project aimed at funding innovative drug research, raw material drug expansion, and supplementing working capital [2][4] - The company is optimizing processes for potential centralized procurement products and building a product matrix that supports innovative drugs and differentiated generics [2] Group 4: Corporate Transactions - 罗欣药业's subsidiary, 山东罗欣, intends to transfer its 100% stake in 山东罗欣乐康制药有限公司 for a consideration of 62.5 million yuan, which will no longer be included in the consolidated financial statements post-transaction [2][4]

Group 1: Financial Performance - The company experienced a significant revenue decline in Q1 2025 due to reduced demand for respiratory and antibiotic products caused by a warm winter [2][3] - In Q4 2024, the company reported substantial losses primarily due to asset impairment provisions and fair value changes of financial instruments, which are non-operational impacts [3][5] - The company achieved profitability in Q1 2025, driven by increased sales of the innovative drug, Tegoprazan, and effective collection of receivables, improving cash flow and reducing bad debt losses [3][4] Group 2: Product Development and Pipeline - The innovative drug LX22001 is currently in Phase II clinical trials, while the clinical research report for Pucanatide tablets has been finalized and is moving towards commercialization [2][3] - The company has over 10 generic drugs in development or submitted for approval, which are expected to contribute to future revenue growth [3][4] Group 3: Market Strategy and Growth Plans - The company plans to significantly increase hospital access for its innovative drugs, with a target of a 130% increase in hospital entries by the end of 2024 [3][4] - The company is focusing on optimizing its supply chain and reducing fixed costs through various measures, including organizational restructuring and talent assessment [4][5] Group 4: Shareholder Information - As of May 9, 2025, the total number of shareholders is 31,442 [5]